{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:04:44Z","timestamp":1792037084522,"version":"4.4.0"},"reference-count":37,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Occupational exposure to antineoplastic drugs can lead to long-term adverse effects on workers\u2019 health. A reproducible Canadian surface monitoring program was established in 2010. The objective was to describe contamination with 11 antineoplastic drugs measured on 12 surfaces among hospitals participating in this annual monitoring program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Each hospital sampled six standardized sites in oncology pharmacies and six in outpatient clinics. Ultra-performance liquid chromatography coupled with tandem mass spectrometry was used for cyclophosphamide, docetaxel, doxorubicin, etoposide, 5-fluorouracil, gemcitabine, irinotecan, methotrexate, paclitaxel, and vinorelbine. Platinum-based drugs were analyzed by inductively coupled plasma mass spectrometry; this excludes inorganic platinum from the environment. Hospitals filled out an online questionnaire about their practices; a Kolmogorov\u2013Smirnov test was used for some practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred and twenty-four Canadian hospitals participated. Cyclophosphamide (405\/1445, 28%), gemcitabine (347\/1445, 24%), and platinum (71\/756, 9%) were the most frequent. The 90th percentile of surface concentration was 0.01\u2005ng\/cm\u00b2 for cyclophosphamide and 0.003\u2005ng\/cm\u00b2 for gemcitabine. Centers that prepared 5000 or more antineoplastic per year had higher concentrations of cyclophosphamide and gemcitabine on their surfaces ( p\u2009\u2009=\u2009\u20090.0001). Almost half maintained a hazardous drugs committee (46\/119, 39%), but this did not influence the cyclophosphamide contamination ( p\u2009\u2009=\u2009\u20090.051). Hazardous drugs training was more frequent for oncology pharmacy and nursing staff than for hygiene and sanitation staff.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This monitoring program allowed centers to benchmark their contamination with pragmatic contamination thresholds derived from the Canadian 90th percentiles. Regular participation and local hazardous drug committee involvement provide an opportunity to review practices, identify risk areas, and refresh training.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552231167329","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T03:43:30Z","timestamp":1680752610000},"page":"19-29","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 124 centers"],"prefix":"10.1177","volume":"30","author":[{"given":"Emma","family":"Pinet","sequence":"first","affiliation":[{"name":"Pharmacy Department, CHU Sainte-Justine, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7360-568X","authenticated-orcid":false,"given":"Ciprian Mihai","family":"Cirtiu","sequence":"additional","affiliation":[{"name":"Centre de Toxicologie du Qu\u00e9bec, Institut national de sant\u00e9 publique du Qu\u00e9bec, Quebec, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Caron","sequence":"additional","affiliation":[{"name":"Centre de Toxicologie du Qu\u00e9bec, Institut national de sant\u00e9 publique du Qu\u00e9bec, Quebec, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6623-4967","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Bussi\u00e8res","sequence":"additional","affiliation":[{"name":"Pharmacy Department, CHU Sainte-Justine, Montreal, Quebec, Canada"},{"name":"Faculty of Pharmacy, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0969-6051","authenticated-orcid":false,"given":"Cynthia","family":"Tanguay","sequence":"additional","affiliation":[{"name":"Pharmacy Department, CHU Sainte-Justine, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"bibr1-10781552231167329","doi-asserted-by":"publisher","DOI":"10.4081\/jphr.2021.1993"},{"key":"bibr2-10781552231167329","unstructured":"National Institute for Occupational Safety and Health.\n                      NIOSH list of hazardous drugs in healthcare settings\n                      2020. Publication Number 2020-xxx (Supersedes 2016-161), https:\/\/www.cdc.gov\/niosh\/docket\/review\/docket233c\/pdfs\/DRAFT-NIOSH-Hazardous-Drugs-List-2020.pdf (2020, accessed 17 October 2022)."},{"key":"bibr3-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211034473"},{"key":"bibr4-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211010928"},{"key":"bibr5-10781552231167329","unstructured":"U.S. Pharmacopeial Convention.\n                      General chapter <800> hazardous drugs\u2014handling in healthcare settings USP 39\u2013NF 34, First Supplement\n                      . http:\/\/www.usp.org\/sites\/default\/files\/usp_pdf\/EN\/USPNF\/usp-nf-commentary\/gc__800_commentary_final.pdf (2016, accessed 10 November 2021)."},{"key":"bibr6-10781552231167329","unstructured":"Canadian Society of Hospital Pharmacists.\n                      Compounding: Guidelines for pharmacies (2014)\n                      . https:\/\/www.cshp.ca\/Site\/Resources\/Official-Publications\/Guidelines\/Site\/Content\/Resources\/guidelines.aspx?hkey\u2009=\u2009324de15b-f6c8-4ee2-b100-ac648c36d80f (2014, accessed 28 October 2022)."},{"key":"bibr7-10781552231167329","unstructured":"Association paritaire pour la sant\u00e9 et la s\u00e9curit\u00e9 du travail du secteur affaires sociales.\n                      Guide de pr\u00e9vention \u2013 Manipulation s\u00e9curitaire des m\u00e9dicaments dangereux.\n                      http:\/\/asstsas.qc.ca\/publication\/gp65 (2021, accessed 27 October 2022)."},{"key":"bibr8-10781552231167329","first-page":"107815522110728","volume":"12","author":"Delafoy C","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"bibr9-10781552231167329","first-page":"96","volume":"45","author":"Valero-Garc\u00eda S","year":"2021","journal-title":"Farm Hosp"},{"key":"bibr10-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1093\/annweh\/wxac035"},{"key":"bibr11-10781552231167329","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19148601"},{"key":"bibr12-10781552231167329","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19063737"},{"key":"bibr13-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2020.09.003"},{"key":"bibr14-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221103803"},{"key":"bibr15-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1188\/17.CJON.254-256"},{"key":"bibr16-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1188\/17.CJON.73-78"},{"key":"bibr17-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-022-00250-1"},{"key":"bibr18-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"bibr19-10781552231167329","unstructured":"Sant\u00e9 Canada.\n                      Guidance document. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Validation of Analytical Procedures: Text and Methodology. ICH Topic Q2(R1)\n                      . 2015\/06\/05. Available from: https:\/\/www.canada.ca\/content\/dam\/hc-sc\/migration\/hc-sc\/dhp-mps\/alt_formats\/pdf\/prodpharma\/applic-demande\/guide-ld\/ich\/qual\/q2r1-eng.pdf."},{"key":"bibr20-10781552231167329","unstructured":"Official Journal of the European Union.\n                      Commission Directive 2009\/90\/EC of 31 July 2009 laying down, pursuant to Directive 2000\/60\/EC of the European Parliament and of the Council, technical specifications for chemical analysis and monitoring of water status\n                      . https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri\u2009=\u2009CELEX%3A32009L0090 (2009, accessed 10 November 2021)."},{"key":"bibr21-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1080\/1047322X.1990.10389587"},{"key":"bibr22-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1515\/pthp-2021-0006"},{"key":"bibr23-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1007\/s11356-021-17607-y"},{"key":"bibr24-10781552231167329","first-page":"37","volume":"40","author":"Bussi\u00e8res JF","year":"2007","journal-title":"Pharmactuel"},{"key":"bibr25-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxab412"},{"key":"bibr26-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1007\/s00420-021-01731-w"},{"key":"bibr27-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1186\/s12912-021-00771-4"},{"key":"bibr28-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1007\/s13187-021-02113-z"},{"key":"bibr29-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1016\/j.nedt.2016.11.002"},{"key":"bibr30-10781552231167329","unstructured":"Ordre des pharmaciens du Qu\u00e9bec.\n                      Norme 2014.02 \u2013 Pr\u00e9paration de produits st\u00e9riles dangereux en pharmacie\n                      . 2017 https:\/\/www.opq.org\/materiel-documentation\/norme-2014-02-preparation-de-produits-steriles-dangereux-en-pharmacie\/ (Accessed 28 October 2022)"},{"key":"bibr31-10781552231167329","unstructured":"U.S. Pharmacopeial Convention.\n                      <797> FAQs\n                      . November 1, 2022. https:\/\/go.usp.org\/2022_Revisions_795_797 (Accessed 3 November 2022)."},{"key":"bibr32-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa326"},{"key":"bibr33-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2020-002440"},{"key":"bibr34-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1093\/annweh\/wxz093"},{"key":"bibr35-10781552231167329","doi-asserted-by":"publisher","DOI":"10.1007\/s00420-021-01671-5"},{"key":"bibr36-10781552231167329","first-page":"761","volume":"58","author":"Hon CY","year":"2014","journal-title":"Ann Occup Hyg"},{"key":"bibr37-10781552231167329","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.989977"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231167329","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231167329","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231167329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:28:10Z","timestamp":1777688890000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231167329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1177\/10781552231167329"],"URL":"https:\/\/doi.org\/10.1177\/10781552231167329","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]}}}